Drug Trial Radar · NCT03163966
A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Oct 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
248
Actual
Start
Oct 5, 2017
Primary completion
Jan 8, 2019
Study completion Jan 8, 2019
Sponsor
- Lead sponsor
- Rottapharm BiotechIndustry
- Sponsor type
- Industry
- First posted
- May 23, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CR6086 is a new, potent and selective, orally available, small molecule prostaglandin EP4 receptor antagonist, endowed with immunomodulatory properties. The pharmacological properties of CR6086, along with its oral bioavailability, predictable pharmacokinetics and good safety, make it the ideal candidate to be tested alone or in combination with methotrexate (MTX) in patients with early Rheumatoid Arthritis who are naïve to Disease-Modifying Antirheumatic Drugs (DMARDs). The compound has indeed the potential to provide a safer and more effective treatment than MTX (or other conventional synthetic DMARDs - csDMARDs), and could significantly improve the proportion of responder patients and avoid/delay the recourse to biological DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs).
Conditions
- Rheumatoid Arthritis, DMARD-naive and Early Disease Patients
Interventions
CR6086Drug
oral CR6086 capsules
MethotrexateDrug
oral Methotrexate tablets
PlaceboDrug
oral CR6086 Placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- American College of Rheumatology 20% improvement (ACR20) responder rateTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Rheumatology
Prague, Czechia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.